Clinuvel Pharmaceuticals Ltd ADR (CLVLY) Annual Income Statement ()
CLVLY Quarterly Financials ()
Frequently Asked Questions About Clinuvel Pharmaceuticals Ltd ADR (CLVLY) Stock
Clinuvel Pharmaceuticals Ltd ADR's (CLVLY) last reported annual revenue was USD 78.32 Million.
Clinuvel Pharmaceuticals Ltd ADR's (CLVLY) annual revenue growth rate based on the revenue reported in the past 5 years is : 25.17%
Clinuvel Pharmaceuticals Ltd ADR's(CLVLY) is profitable as of its last reported annual financials.
The net profit margin for Clinuvel Pharmaceuticals Ltd ADR's(CLVLY) from its laster reported year is 39.08%
The return on equity (ROE) for Clinuvel Pharmaceuticals Ltd ADR's(CLVLY) from its last reported annual financials is : 18.98%
The return on assets (ROA) for Clinuvel Pharmaceuticals Ltd ADR's(CLVLY) from its last reported annual financials is : 14.71%
The return on invested capital (ROIC) for Clinuvel Pharmaceuticals Ltd ADR's(CLVLY) from its last reported annual financials is : 17.87%
The Debt to Equity ratio for Clinuvel Pharmaceuticals Ltd ADR's(CLVLY) from its last reported annual financials is : 0.00%
The dividend yield for Clinuvel Pharmaceuticals Ltd ADR's(CLVLY) from its laster reported year is 0.34%
Clinuvel Pharmaceuticals Ltd ADR's(CLVLY) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CLVLY !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
